Summary by Futu AI
Novo Nordisk A/S, a leading global healthcare company, has been actively executing its share repurchase program, which was announced on May 6, 2024. As part of a larger 12-month share repurchase initiative with a budget of up to DKK 20 billion that started on February 6, 2024, the company has been buying back B shares. From May 7, 2024, to August 5, 2024, Novo Nordisk is set to repurchase B shares worth up to DKK 2.2 billion. The latest transactions, reported on July 29, 2024, show that since the last announcement on July 22, 2024, the company has acquired an additional 201,500 B shares, spending approximately DKK 181,490,215. This brings the total repurchased under the program to 2,086,287 B shares at a cost of DKK 1,980,536,332. Novo Nordisk now holds 12,186,327 B shares as treasury shares, which is 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange.